Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0086543 (
cataract
)
29,165
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A patient had bilateral cataracts and severe plasma thromboplastin antecedent deficiency (
factor XI
deficiency). This patient underwent successful
cataract
extraction in both eyes without complication. The problems inherent in performing eye surgery with
factor XI
deficiency are discussed.
...
PMID:Ophthalmic surgery and plasma thromboplastin antecedent (factor XI) deficiency. 737 9
Factor XI
(
FXI
) inhibitors are a rare complication of inherited
FXI
deficiency. We report the successful use of recombinant factor VIIa (FVIIa) in a patient with a high-responding inhibitor undergoing
cataract
extraction. At the time of surgery there were limited available data on the optimal management of patients with
FXI
deficiency. A 62-year-old Ashkenazi Jewish woman had a lifelong history of excessive bleeding secondary to severe
FXI
deficiency (2 U dL-1), and received
FXI
concentrate (
FXI
:C) when she underwent a colposuspension procedure. She was subsequently diagnosed with a
FXI
inhibitor of 16 Bethesda units (BU) when she developed a poor response to
FXI
:C at the time of total hip replacement. Two months later she was admitted for
cataract
extraction. The
FXI
level was < 1 U dL-1 with an inhibitor titre of 48 BU. She received 90 microg kg-1 of FVIIa immediately preoperatively followed by continuous infusion at a rate of 20 microg kg-1 h-1 for 24 h. The
cataract
extraction was successful and there was no excess bleeding during surgery or in the postoperative period. Mutation analysis of the
FXI
gene showed that the patient was homozygous for the type II genotype [exon 5, Glu117-->Ter]. The reason for the low prevalence of inhibitor formation in patients with
FXI
deficiency is unclear but may reflect a number of factors including reporting bias, the rarity of absent circulating
FXI
:C activity, and the infrequent use of
FXI
replacement therapy.
...
PMID:Successful use of recombinant factor VIIa in a patient with inhibitor secondary to severe factor XI deficiency. 1195 51